What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1190536

Cover Image

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1190536

Defibrillator Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

PAGES: 110 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

Contact us about how to customize the report with add-on data.

The defibrillator market is expected to register a CAGR of 6.8% over the forecast period.

The COVID-19 epidemic has altered several facets of the healthcare system, including how people are treated for cardiac arrests both outside and within hospitals. With the onset of the pandemic the global economy has been affected in three ways, directly affecting production and demand, disrupting the supply chain, and financial impact on firms and financial markets due to strict lockdowns. Delays in the delivery of products and services have been seen as newer packaging protocols and lockdown measures were implemented in many countries. All these factors negatively impacted the manufacturing and supply chain of the defibrillators market. However, the increasing use of defibrillators during the pandemic positively impacted the market. For instance, as per the article titled "Barrier resuscitation by lay rescuers during COVID-19 pandemic" published in September 2021, the severe acute respiratory syndrome-associated coronavirus type 2 (SARS-CoV-2) pandemic will have a long-term impact on basic life support and put an end to mouth-to-mouth breathing as it has been practiced up to this point. Basic life support provided by lay rescuers during the COVID-19 pandemic is now only allowed to consist of compressions and the use of an automatic external defibrillator, according to the most recent interim international resuscitation standards. Therefore, such instances indicate that the market witnessed moderate growth during the pandemic.

The increasing prevalence of cardiovascular diseases and technological advancements in the field of defibrillators are the major drivers for the market. For instance, according to the World Heart Federation published in 2022, cardiovascular disease, including heart disease and stroke, is the most common non-communicable disease globally, responsible for nearly 18.6 million deaths, of which more than three-quarters occur in low- and middle-income countries. Similarly, according to the report published by the Centers for Disease Control and Prevention (CDC) in 2021, it stated that heart disease is one of the leading causes of death for women, men, and most racial and ethnic groups in United States. It also reported that one person dies every 36 seconds in United States due to cardiovascular diseases. It also reported that around 659,000 people in United States die from heart disease every year which is 1 out of every 4 deaths. Mortality due to cardiovascular diseases such as strokes and heart attacks mainly occurs when the patient fails to receive immediate help from professionals. In cardiac arrest, the brain and other vital organs are unable to receive sufficient blood. Therefore, this requires treatment within minutes to prevent death. Defibrillators help to revive patients from sudden cardiac arrest by providing sufficient oxygen and blood to the required organs via sudden shock. Therefore, increasing cases of cardiovascular diseases and alarming mortality rate due to cardiovascular diseases is expected to propel the demand for defibrillators, thereby propelling the market growth over the forecast period.

However, the stringent regulatory framework is likely to hinder market growth over the forecast period.

Defibrillator Market Trends

Fully Automated External Defibrillator is Expected to Witness Growth Over the Forecast Period

A fully automated external defibrillator (AED) is designed to automatically deliver a shock when needed without the rescuer having to press a button to deliver the shock. The device communicates step-by-step instructions to let rescuers know when the victim is about to receive a shock. Fully automatic models are designed to assist responders in cardiac arrest emergencies. Many studies have shown that fully automatic AEDs are safe, and effective, and can reduce extended delays associated with hesitating to press the shock button during a rescue.

The product launches by key players and the increasing use of fully automated external defibrillators are the major factors driving the segment's growth. For instance, in June 2020, Royal Philips announced that the Center for Devices and Radiological Health (CDRH) of United States Food and Drug Administration (FDA) has granted premarket approval (PMA) for the company's HeartStartFR3 and HeartStart FRx automated external defibrillators (AEDs), and their supporting accessories, including batteries and pads. Similarly, according to the report published by the National Conference of State Legislatures in August 2020, several states have proposed or passed legislation requiring AEDs to be located in health clubs and gyms, at school athletic events, or in other public areas. It also reported that many states of United States have considered how to encourage wider availability of AEDs, including provisions that encourage or require training in AED use, require maintenance and testing to meet manufacturers' standards, create a registry of defibrillator locations, establish a "Good Samaritan" exemption from responsibilities and authorizes state authorities to set more detailed training requirements. and registration. The advocates have also encouraged the placement of AEDs in public buildings, transportation centers, and large offices or apartment buildings. Thus, such factors are anticipated to surge the segment growth over the forecast period.

North America is Expected to Dominate the Defibrillator Market Over the Forecast Period

North America is expected to dominate the overall defibrillator market over the forecast period. The growth is due to factors such as increased heart diseases in the region, the presence of key companies operating in the defibrillator market, and increasing healthcare expenditure. For instance, as per the February 2022 report from the Heart and Stroke Foundation of Canada, 750,000 people are living with heart failure, and 100,000 people are diagnosed with this incurable condition each year in the country and it is projected that by the year 2030, the healthcare costs associated with heart failure in Canada will reach up to USD 2.8 billion per year. Hence, with this high number of heart patients along with the increasing economic burden due to heart failure in the country, the market is expected to witness high growth over the forecast period in this region.

Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing cases of cardiac arrest in United States are some of the factors driving the growth of the defibrillators market in the country. For instance, as per the 2020 data from the Centers for Disease Control and Prevention, every year, 805,000 people in United States suffer from a heart attack, 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. With this increasing burden of heart disease in the country, demand for defibrillators is on the rise which is propelling the growth of the market in the country.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Defibrillator Market Competitive Analysis

The defibrillator market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Boston Scientific Corporation, Koninklijke Philips NV, Medtronic PLC, Nihon Kohden Corporation, and Abbott Laboratories among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 61708



  • 1.1 Study Assumptions and Market Defination
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cardiovascular Diseases
    • 4.2.2 Technological Advancements in the Field of Defibrillators
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product
    • 5.1.1 Implantable Cardioverter Defibrillator (ICD)
      • Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
      • Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
      • CRT with Pacemaker and ICD Function (CRT-D)
    • 5.1.2 External Defibrillator (ED)
      • Automated External Defibrillator (AEDs)
      • Semi-automated External Defibrillators
      • Fully-automated External Defibrillators
    • 5.1.3 Manual External Defibrillator
      • Wearable Cardioverter Defibrillators (WCDs)
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Emergency Care
    • 5.2.3 Home Care
    • 5.2.4 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Cardiac Science Corporation
    • 6.1.4 Defibtech LLC
    • 6.1.5 Koninklijke Philips NV
    • 6.1.6 LivaNova PLC
    • 6.1.7 Medtronic PLC
    • 6.1.8 Nihon Kohden Corporation
    • 6.1.9 Physio-Control Inc.
    • 6.1.10 ZOLL Medical Corporation
    • 6.1.11 Bexen Cardio
    • 6.1.12 Mindray Medical International Ltd.


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!